Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer.

Hisao ImaiErika NaitoOu YamaguchiKosuke HashimotoHidetoshi IemuraYu MiuraAyako ShionoAtsuto MouriKyoichi KairaKunihiko KobayashiHiroshi Kagamu

Published in: Thoracic cancer (2022)

Among patients with NSCLC treated with nivolumab monotherapy as second-line treatment, PS was significantly correlated with both PFS and OS and BMI with OS. Thus, BMI could be a useful predictor of survival in these patients.

Keyphrases

body mass index
combination therapy
end stage renal disease
newly diagnosed
weight gain
ejection fraction
small cell lung cancer
chronic kidney disease
open label
peritoneal dialysis
physical activity
prognostic factors
clinical trial
randomized controlled trial
patient reported outcomes